ArticleClinical rheumatology2020
Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Biologic therapies for the treatment of large vessel vasculitis: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Quantitative assessment of intrapulmonary vessel volume by CTPA in vasculitis patients with pulmonary vascular involvement.BMC medical imaging · 2026Article
- Improving outcomes in proximal anastomosis: A challenging case of coronary revascularization in Takayasu arteritis.JTCVS techniques · 2025Article
- Challenges in Diagnosis and Management of Takayasu Arteritis: A Case Report Highlighting Vascular Complications and Delayed Recognition.Clinical case reports · 2025Article
- [C-reactive protein, cardiovascular issues of an acute-phase protein: an update for theclinician].Archivos de cardiologia de Mexico · 2024Review
- Unveiling the mystery: a rare case of localized malignant pericardial mesothelioma-case report.Frontiers in oncology · 2024Article
- Isolated Coronary Arteritis Treated With FDG-PET/CT-Guided Immunosuppressant to Break the Vicious Cycle of In-Stent Restenosis.JACC. Case reports · 2023Article
- C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine.Biomedicines · 2023Review
- High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study.Arthritis research & therapy · 2023Observational
- Coronary artery lesions in Takayasu arteritis.Reumatologia · 2023Review
- Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review.Heart and vessels · 2022Review
- Acute Coronary Syndrome Developed in a 17-year-old Boy with Sitosterolemia Comorbid with Takayasu Arteritis: A Rare Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2022Review
- Tocilizumab for faster and safer remission of Takayasu's arteritis.Therapeutic advances in chronic disease · 2022Article
- Coronary Vasculitis.Biomedicines · 2021Review
- Coronary artery vasculitis: a review of current literature.BMC cardiovascular disorders · 2021Review
- Numano type V Takayasu arteritis patients are more prone to have coronary artery involvement.Clinical rheumatology · 2020Article
- Commentary: Game, set, patch?JTCVS techniques · 2020Article
- Cardiovascular Manifestations of Systemic Vasculitides.Current rheumatology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveCoronary artery involvement in Takayasu arteritis (TAK) leads to poor prognosis and high mortality. Tocilizumab (TCZ) has been used to effectively treat large vessel vasculitis. However, the efficacy of TCZ in resolving coronary artery involvement in TAK is unclear. The aim of this retrospective study was to evaluate the efficacy of TCZ in the treatment of coronary artery involvement in TAK.
methodsClinical features and manifestations of coronary artery lesions in 11 TAK patients were evaluated before and after TCZ treatment, and the results were compared with those of 11 patients treated with traditional disease-modifying antirheumatic drugs (DMARDs).
resultsC-reactive protein (p = 0.006), erythrocyte sedimentation rate (ESR) (p = 0.011), and Kerr score (p = 0.007) were significantly decreased post-TCZ treatment for 6 months. The Indian Takayasu Clinical Activity Score (ITAS) 2010 (p = 0.019) and ITAS-A (p = 0.019) were significantly lower in patients treated with TCZ compared with those treated with traditional DMARDs. The glucocorticoid (GC) dose was tapered to 2.50 (0.00, 7.50) mg day
conclusionTCZ may decrease the disease activity and improve coronary artery lesion in patients with TAK. Key Points • TCZ treatment significantly decreased the disease activity in TAK patients with coronary artery involvement. • TCZ treatment significantly reduces the dosage of GC. • TCZ treatment led to an improvement in imaging findings of TAK patients with coronary artery involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.